SG10202002971SA - Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells - Google Patents

Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells

Info

Publication number
SG10202002971SA
SG10202002971SA SG10202002971SA SG10202002971SA SG10202002971SA SG 10202002971S A SG10202002971S A SG 10202002971SA SG 10202002971S A SG10202002971S A SG 10202002971SA SG 10202002971S A SG10202002971S A SG 10202002971SA SG 10202002971S A SG10202002971S A SG 10202002971SA
Authority
SG
Singapore
Prior art keywords
transbiosis
heterochronic
methods
stem cells
pluripotent stem
Prior art date
Application number
SG10202002971SA
Inventor
K Burt Richard
Original Assignee
K Burt Richard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K Burt Richard filed Critical K Burt Richard
Publication of SG10202002971SA publication Critical patent/SG10202002971SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202002971SA 2015-09-29 2016-09-29 Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells SG10202002971SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562234444P 2015-09-29 2015-09-29

Publications (1)

Publication Number Publication Date
SG10202002971SA true SG10202002971SA (en) 2020-05-28

Family

ID=58523381

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202002971SA SG10202002971SA (en) 2015-09-29 2016-09-29 Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells
SG10201608144UA SG10201608144UA (en) 2015-09-29 2016-09-29 Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201608144UA SG10201608144UA (en) 2015-09-29 2016-09-29 Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells

Country Status (3)

Country Link
US (2) US10813955B2 (en)
BR (1) BR102016022647A2 (en)
SG (2) SG10202002971SA (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813955B2 (en) 2015-09-29 2020-10-27 Genani Corporation Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
WO1999027076A1 (en) 1997-11-25 1999-06-03 Arc Genomic Research Pluripotent embryonic stem cells and methods of obtaining them
US20030161817A1 (en) 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
CA2465672A1 (en) * 2001-09-19 2003-03-27 Henry Ford Health System Cardiac transplantation of stem cells for the treatment of heart failure
NZ534540A (en) 2002-02-06 2005-07-29 Stiftung Caesar Described is the development of a stem cell bank for teeth or teeth derived tissues, as well as the development of membrane-like meso/endodermal matrices which can be used in regenerative medicine
WO2004003142A2 (en) 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050249731A1 (en) 2002-07-16 2005-11-10 Hadi Aslan Methods of implating mesenchymal stem cells for tissue repair and formation
NZ597965A (en) 2003-10-08 2013-09-27 Vet Stem Inc Methods of preparing and using stem cell compositions and kits comprising the same
PL1835924T3 (en) 2004-12-23 2014-01-31 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
US20070092494A1 (en) 2005-10-26 2007-04-26 Biomet Manufacturing Corp. Composition for wound healing using lyophilized skin or skin-derived collagen
US8871198B2 (en) 2006-03-29 2014-10-28 Stemnion, Inc. Methods related to wound healing
US20070292401A1 (en) 2006-06-20 2007-12-20 Harmon Alexander M Soft tissue repair and regeneration using stem cell products
RU2009105890A (en) 2006-07-20 2010-08-27 Ричард БЕРТ (US) METHOD FOR APPLICATION OF MITOTICALLY INACTIVATED STEM CELLS FOR REPAIR OF DAMAGED TISSUE
CN101156944A (en) 2006-10-07 2008-04-09 于廷曦 Cleavage liquid for preventing and curing nervus energy disease scathing nervus stem cell
US20080241113A1 (en) 2007-03-01 2008-10-02 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of endometrial/menstrual cells
US20110020291A1 (en) 2007-11-17 2011-01-27 Debrabrata Banerjee Use of stem cells for wound healing
CN101449822A (en) 2007-12-05 2009-06-10 詹承镇 Embryo telomerase food
US20100040583A1 (en) 2008-03-27 2010-02-18 Vincent Falanga Compositions and methods using stem cells in cutaneous wound healing
US8790638B2 (en) 2009-02-04 2014-07-29 Stemedica Cell Technologies, Inc. Compositions of stem cells and stem cell factors and methods for their use and manufacture
US20120141433A1 (en) 2010-10-06 2012-06-07 Nikolai Tankovich Vaporized Stem Cell Derivatives for Topical and Other Therapeutic Uses
WO2013142192A1 (en) * 2012-03-19 2013-09-26 Richard Burt Methods and compositions for regenerating and repairing damaged tissue using nonviable irradiated or lyophilized pluripotent stem cells
US10596202B2 (en) 2012-09-19 2020-03-24 Microvascular Tissues, Inc. Compositions and methods for treating and preventing tissue injury and disease
US9872937B2 (en) 2012-09-19 2018-01-23 Microvascular Tissues, Inc. Compositions and methods for treating and preventing tissue injury and disease
CN103751228B (en) 2014-01-27 2016-04-20 贵州神奇药物研究院 Medicine for the treatment of senile dementia and preparation method thereof
US10813955B2 (en) 2015-09-29 2020-10-27 Genani Corporation Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells

Also Published As

Publication number Publication date
US20170106024A1 (en) 2017-04-20
SG10201608144UA (en) 2017-04-27
BR102016022647A2 (en) 2017-04-04
US10813955B2 (en) 2020-10-27
US10828338B2 (en) 2020-11-10
US20180296610A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
IL248299A0 (en) A method and kit for determining the tissue or cell origin of dna
HK1251181A1 (en) Methods of tissue repair and regeneration
IL250132A0 (en) Method for inducing t cells for immunocytotheraphy from pluripotent stem cells
GB2536538B (en) Anchor for implantation in body tissue
PL3145517T3 (en) Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same
EP3138399C0 (en) Composition for organ, tissue, or cell transplantation, kit, and transplantation method
EP3384007C0 (en) Improved methods for reprograming non-pluripotent cells into pluripotent stem cells
HK1245662A1 (en) Methods of treating tissue calcification
PT3174563T (en) Tissue graft
LT3586821T (en) Stem cell stimulating compositions and methods
HK1258528A1 (en) Methods and compositions for stem cell transplantation
EP3872164C0 (en) Isolating stem cells from adipose tissue
HK1254588A1 (en) Use of mesenchymal stem cells in treating osteoarthritis
RS63786B1 (en) Stem cell stimulating compositions and methods of treating melasma
GB201805287D0 (en) Haematoietic stem cell treatment
EP3134096A4 (en) Methods of enhancing stem cell engraftment
SG10202002971SA (en) Methods for treating age-related organ or tissue dysfunction through heterochronic transbiosis using nonviable pluripotent stem cells
EP3389715A4 (en) Compositions and methods for treating cardiac dysfunction
EP3206498A4 (en) Methods for conducting stimulus-response studies with induced pluripotent stem cells derived from perinatal cells or tissues
ZA201607027B (en) Method for treating or enhancing muscle tissue
HK1232131A1 (en) Somatic stem cells for treating bone defects
PL3322480T3 (en) Lactobacilli for treating cardiac dysfunction
GB201414992D0 (en) Resetting human pluripotent stem cells